According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets initiated coverage on shares of Neos Therapeutics in a research report on Tuesday, June 28th. They issued an outperform rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Neos Therapeutics has a consensus rating of Buy and a consensus price target of $21.75.
Neos Therapeutics (NASDAQ:NEOS) opened at 6.76 on Wednesday. The firm’s market cap is $108.63 million. Neos Therapeutics has a 1-year low of $6.33 and a 1-year high of $19.29. The company has a 50-day moving average of $7.06 and a 200-day moving average of $8.67.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The firm earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. Analysts predict that Neos Therapeutics will post ($5.39) earnings per share for the current year.
In related news, CFO Richard I. Eisenstadt bought 3,710 shares of Neos Therapeutics stock in a transaction dated Thursday, August 25th. The shares were bought at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the transaction, the chief financial officer now owns 3,710 shares of the company’s stock, valued at $25,302.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.85% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management Inc. bought a new position in shares of Neos Therapeutics during the second quarter worth about $603,000. State Street Corp increased its stake in Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock worth $972,000 after buying an additional 39,705 shares during the period. ProShare Advisors LLC increased its stake in Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock worth $126,000 after buying an additional 1,233 shares during the period. Perceptive Advisors LLC increased its stake in Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock worth $4,611,000 after buying an additional 526,876 shares during the period. Finally, Teachers Advisors Inc. increased its stake in Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock worth $203,000 after buying an additional 16,296 shares during the period. Institutional investors own 37.73% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.